Европейский союз - английский - EMA (European Medicines Agency)

hikma farmaceutica (portugal) s.a. - voriconazole - bacterial infections and mycoses; aspergillosis; candidiasis - antimycotics for systemic use - voriconazole is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct)recipients.

Малайзия - английский - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - letermovir -

Малайзия - английский - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - letermovir -

Соединенные Штаты - английский - NLM (National Library of Medicine)

melinta therapeutics, llc - delafloxacin meglumine (unii: n7v53u4u4t) (delafloxacin - unii:6315412yvf) - delafloxacin 450 mg - baxdela is indicated in adults for the treatment of acute bacterial skin and skin structure infections (absssi) caused by the following susceptible microorganisms: staphylococcus aureus (including methicillin-resistant [mrsa] and methicillin-susceptible [mssa] isolates), staphylococcus haemolyticus, staphylococcus lugdunensis, streptococcus agalactiae , streptococcus anginosus group (including streptococcus anginosus , streptococcus intermedius , and streptococcus constellatus ), streptococcus pyogenes , enterococcus faecalis , escherichia coli, enterobacter cloacae, klebsiella pneumoniae, and pseudomonas aeruginosa. baxdela is indicated in adults for the treatment of community-acquired bacterial pneumonia (cabp) caused by the following susceptible microorganisms: streptococcus pneumoniae, staphylococcus aureus (methicillin-susceptible [mssa] isolates only), klebsiella pneumoniae , escherichia coli, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae , chlamydia pneumoniae , legione

Европейский союз - английский - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19

Сингапур - английский - HSA (Health Sciences Authority)

viatris private limited - sildenafil citrate 70.225mg eqv. sildenafil - tablet, orally disintegrating - 50mg - sildenafil citrate 70.225mg eqv. sildenafil 50mg

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

vantive limited - calcium chloride dihydrate 257 mg/l; icodextrin 75 g/l; magnesium chloride hexahydrate 51 mg/l; sodium chloride 5.4 g/l; sodium lactate 4.5 g/l - dialysis solution - 7.5% w/v - active: calcium chloride dihydrate 257 mg/l icodextrin 75 g/l magnesium chloride hexahydrate 51 mg/l sodium chloride 5.4 g/l sodium lactate 4.5 g/l excipient: hydrochloric acid sodium hydroxide water for injection

Европейский союз - английский - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - community-acquired infections - antibacterials for systemic use, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1).consideration should be given to official guidance on the appropriate use of antibacterial agents.